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ECT is the most acutely effective treatment for treatment-resistant, sometimes life-threatening, depression (2, 3) . Nevertheless, its use remains limited, mainly because of cognitive sideeffects (4) , especially concerns about retrograde amnesia (5, 6) .
Research on electrode placement has focused on preserving efficacy and minimising side-effects. Based on dosage, right unilateral ECT is less effective than bitemporal ECT (2), the most commonly used electrode placement worldwide (1) , but causes less cognitive deficits (7) . High-dose is more effective than low-dose ECT but more adversely affects memory (2, 7) .
However, recent efficacy trials (8) (9) (10) (11) (12) (13) have demonstrated that unilateral ECT can be as effective as bitemporal ECT if delivered in high doses at multiples (e.g. 5-8x) of seizure threshold, the minimum charge required to induce the generalised seizure needed for therapeutic effect.
Although unilateral ECT causes fewer cognitive side-effects, the higher charges required to achieve comparable antidepressant efficacy might diminish its cognitive advantage.
Relevant trials of brief-pulse (i.e. 1.0-1.5 msec pulse width) ECT have obtained inconsistent results: some show comparable cognitive performance following high-dose (5-8xthreshold) unilateral ECT with reference to moderate-dose (1.0-1.5xthreshold) bitemporal ECT (9, 10, 13) while others demonstrate less cognitive decline following high-dose (6xthreshold) unilateral ECT (8, 11, 12) , although the latter studies mostly compared it with higher dose (2.5xthreshold) bitemporal ECT that increases cognitive side-effects (7) . None of these studies was designed to determine unilateral non-inferiority for antidepressant effect and most had very limited follow-up. All used thrice-weekly treatment, common practice in the USA where P e e r R e v i e w O n l y 6 most of these trials originated, even though this does not result in better outcomes than twiceweekly ECT (14) but is associated with increased cognitive side-effects (15). This limits their generalisability for populations where twice-weekly frequency is common practice, as occurs in many European countries, e.g. Belgium, Ireland, The Netherlands, UK (16, 17) .
Additionally, none of the previous trials reflected routine practice in that antidepressants were stopped before ECT and all but one (9) required receiving at least eight ECT sessions unless response criteria were met.
To date, no randomised trial has tested whether twice-weekly high-dose (6xthreshold) unilateral ECT is non-inferior to reference (1.5xthreshold) bitemporal ECT nor evaluated its superiority in terms of cognition and retrograde memory preservation over a prolonged followup period. We aimed to examine short and long-term effectiveness and cognitive side-effects of high-dose unilateral ECT compared with bitemporal ECT for severe depression in routine practice over six-months.
METHOD Study design and participants
EFFECT-Dep was a pragmatic, patient-and rater-blinded, two-group, parallel, randomised, non-inferiority trial, with six-month follow-up (18, 19 inability/refusal to consent. Treatment during the follow-up period was determined by patients in consultation with treating clinicians. This study was approved by the hospital's Research Ethics Committee (012/07) and written informed consent obtained after procedures were fully explained.
Randomisation and masking
After baseline assessments and before the first ECT session, patients were allocated (1:1) to bitemporal or unilateral ECT using an online system by the Clinical Trials Unit, King's College London. Minimisation with variable block sizes ensured group allocation was balanced regarding three stratifiers: age>65 (yes/no); previous ECT (yes/no); referral site (St Patrick's Mental Health Services/St James's Hospital/other hospital). Recruiting researchers electronically submitted participants' identifying number, initials, birthdate, history of ECT, and referral site. Treating clinicians received e-mail notification of randomisation but were not involved in outcome assessments. Allocation was concealed from patients (prepared for receiving both electrode placements), recovery staff, referring clinicians, assessors and trial statistician until completion of final analyses. Success of masking was investigated after endof-treatment assessments by asking patients and raters to guess the treatment used.
Interventions
Brief-pulse (1.0 msec pulse width; current amplitude 800 mA) ECT was administered twice- 
Primary outcome
The primary outcome was depression severity measured by HAM-D24 after completing the ECT course (end-of-treatment). Inter-rater reliability for HAMD-24 scoring was assessed every six-months; median intraclass correlation agreement was 0.96 (range 0.89-0.98). To classify depression status, HAMD-24 scores were obtained after every second ECT session and one-
week after the final session if indicated.
Secondary outcomes
Secondary depression outcomes included HAM-D24 scores at three-and six-month followups; end-of-treatment remission and response status; and relapse status for remitters during sixmonth follow-up. Remission was defined as ≥60% decrease from baseline HAM-D24 and score ≤10 for two consecutive weeks; response as ≥60% decrease from baseline HAM-D24 and score ≤16; and relapse as HAM-D24 ≥16 for two consecutive weeks. The majority of patients who relapse following successful ECT do so within three-months (26). To monitor relapse, HAM-D24 scores were obtained after end-of-treatment at: 2, 4, 6 and 8 weeks plus 3, 4 and 6 months. at baseline, end-of-treatment, and three-and six-month follow-ups. These outcomes, as well as the HAM-D24, were similar to ones used to establish efficacy and side-effects of bitemporal ECT (7, 8, (11) (12) (13) 16 ).
Subjective symptoms attributable to ECT were assessed with the Columbia ECT Subjective Side-Effects Schedule, including six items on memory, concentration and orientation for self-rating of cognition (total=18)(28).
Sample size
Based on a large bitemporal ECT series (29), we estimated 69 patients were required per group to have 80% power to demonstrate, using a one-sided equivalence t-test at 5% level, that the mean reduction in HAM-D24 following high-dose unilateral ECT was no more than 4-points (i.e. equivalent to 3-points on HAM-D17, deemed to be clinically relevant (30)) less that achieved using bitemporal ECT.
Statistical analyses
Analyses were on the intention-to-treat principle. ECT measures were summarised by trial arm using relevant descriptive statistics, accompanied by tests of zero group difference where this was not known a priori. We formally compared total numbers of sessions, numbers of sessions to establish seizure threshold (coded "1" or "≥2" sessions) and time to recovery-of-orientation P e e r R e v i e w O n l y 11 using regression, logistic regression and regression of log-transformed times respectively. In these regression models, randomisation stratifiers were included as explanatory variables in addition to trial arm.
The primary statistical analysis was assessment of difference in HAM-D24 scores between arms at end-of-treatment. The estimated group difference was supplemented by 95% confidence intervals and this interval compared to the non-inferiority threshold (4 points). A regression model was fitted to end-of-treatment HAMD-24 measures with pre-randomization HAMD-24, trial arm (unilateral/bitemporal) and randomisation stratifiers as covariates. A similar analysis model was assumed for secondary HAM-D24 outcomes at three-and sixmonths follow-up. Within remitters, relapse during six-month follow-up was compared between arms using logistic regression as above.
The main secondary cognitive outcomes of interest -Autobiographical Memory
Interview at end-of-treatment, three-and six-month follow-ups -were analysed using generalised linear models with a binomial distribution and logit-link (31). Post-treatment Autobiographical Memory Interview measures provide the number of baseline items recalled after ECT (27); such "number of items recalled" variables were therefore modelled as arising from binomial distributions, with maximum number of possible recalls set to the number of items obtained at baseline. An overdispersion parameter was introduced to account for recall of individual events being driven by subject characteristics. The covariates of these models were trial arm and randomisation stratifiers.
Similar regression models were employed to describe non-prioritised continuous secondary outcomes -other cognitive tasks and subjective side-effects (now also including baseline values as covariate). Time outcomes (i.e. Trails A and B) were log-transformed before analysis to acknowledge positively-skewed distributions. The same approach was applied for count outcomes displaying positive skewness (Subjective Side-Effects total and cognitive . Group effects for these outcomes were therefore quantified by the ratio of outcome in the bitemporal arm to that in the unilateral arm.
For physical-safety analyses, we assessed proportions of patients who had adverse events by treatment-group and compared proportions using logistic regression modelling as for ECT measures.
Handling of missing data is described in Supplemental Material. We used Stata (version 13) and SPSS 19.0 (IBM Corp, NY) for statistical analyses. All patients adhered to allocated treatment, although five (7.2%) unilateral patients had thresholds >200mC (225mC, N=1; 250mC, N=3; 500mC, N=1) and so could not be treated at fully 6xthreshold. Nearly all participants (N=136; 98.6%) were assessed for primary outcome at end-of-treatment while 82% and 76% were followed-up respectively at three-and six-months. Treatment guesses were made by patients (119/138) and raters (118/138): 12 patients couldn't guess; 26/56 of the unilateral group and 36/51 in bitemporal group correctly guessed (χ2=3.27, p=0.07, Kappa=0.17 (low coefficient of beyond-chance agreement)). For raters, 30/57 of guesses for the unilateral group and 36/61 for bitemporal group were correct (χ2=1.61, p=0.21, Kappa=0.12). Thus masking was successful for patients and raters.
RESULTS

Participant flow
Baseline and treatment characteristics
Summaries of baseline characteristics were comparable between trial arms as would be expected under random allocation (Table 1) . Age (56.7[14.8] years), gender (63% female), psychosis-status (21%), bipolarity (23%), baseline HAM-D24 (29.9[6.2]), and depression episode median duration (19.5 weeks) for total sample were similar to previous relevant trials (8, 9, (11) (12) (13) and large observational studies (5, 29) . Tables 1 and 2 here Anaesthesia doses were similar for the two groups ( Table 2 ). In line with previous studies (8-12), we found threshold was lower with unilateral ECT, total stimulus charges were higher in the unilateral group, while seizure durations were similar between groups. 93% of between groups for total number of ECT sessions (p=0.26). Median time to recovery-oforientation following the initial titration-session in the unilateral group was half that of bitemporal group (p<0.001) and this cognitive advantage was maintained, though to a lesser extent, during remainder of the course. 29/69 (42.0%)) in the two groups at end-of-treatment. The median number of ECT sessions for both responders and remitters was 7 (range 3-12) and was less than for both non-responders and non-remitters at 9 (range 3-12) (for both Mann-Whitney U test, p<0.001). During the sixmonth follow-up there was no significant difference between proportions of remitters who Table S3 .
Primary and secondary mood outcomes
Cognitive secondary outcomes
Assessment completion levels varied for non-prioritised secondary outcomes. End-oftreatment completion rates ranged from 93.5% (category fluency) to 71.7% (verbal learning).
Three-month completion rates varied from 62.3% (category fluency) to 47.8% (Trail-Making B), and at six-months from 59.4% (category fluency) to 42.8% (Trail-Making B).
There were few differences between groups for the other cognitive tasks (Table S4) .
At end-of-treatment the only statistically significant difference was for better performance in the unilateral group on verbal learning for immediate recall (p=0.034) though not delayed recall (p=0.22). There were no differences between groups on these verbal learning and memory tasks at three-and six-month follow-ups. At three-months performance was better in There were no significant differences between groups on the Subjective Side-Effects Schedule for total side-effects at any timepoint (Table S4 ) although number and severity of side-effects declined substantially over time, probably in line with improved mood (16, 28).
However, significantly fewer subjective cognitive side-effects were reported by the unilateral group at end-of-treatment (p=0.02) and after six-months (p=0.025). Thus there were both objective and subjective cognitive advantages for unilateral compared to bitemporal ECT.
Adverse events
There were no differences between unilateral and bitemporal groups for occurrence of 
DISCUSSION
Our findings show that twice-weekly high-dose unilateral ECT is non-inferior to bitemporal ECT for severe depression in regular clinical practice, which included continued antidepressant pharmacotherapy, and this was maintained over six-months. The proportions of responders and remitters, as well as relapse rates, are consistent with this. Furthermore, we found high-dose unilateral ECT to be less taxing on autobiographical memory than bitemporal ECT. The unilateral group showed significantly higher autobiographical memory consistency with baseline recall than the bitemporal group at end-of-treatment, and three-and six-month followups. Other cognitive advantages of unilateral ECT included quicker recovery-of-orientation following treatments, better verbal learning at end-of-treatment, and fewer subjective cognitive side-effects. Both forms of ECT were well-tolerated. Numbers of common physical side-effects and serious adverse events were similar in both groups, in line with previous studies reporting harms (12, 32).
Our findings for the primary outcome, HAM-D24, are consistent with results of previous, non-pragmatic, thrice-weekly efficacy trials (8) (9) (10) (11) (12) (13) . However, the overall remission rate (44.2%) was lower than in some trials (range 46-65%) (8, 9, (11) (12) (13) ) but similar to that in a large community study (46.7%) (33) while the overall six-month relapse rate (31.1%) was at the lower limit reported in a recent meta-analysis of post-ECT relapse (26). These differences most likely reflect the pragmatic nature of our trial, where number of treatments was decided by patients and referring physicians rather than by protocol as well as a naturalistic follow-up, and are unlikely to be related to concomitant use of antidepressants, which may improve ECT efficacy (12). Cognitive outcomes at end-of-treatment were consistent with previous thriceweekly ECT trials (8, 9, 11, 12) . Regarding autobiographical memory, as measured by the Autobiographical Memory Interview, our findings differed only from two previous trials (9, 13) that found both treatments had comparable effects. This might be explained by the higher 18 stimulus charge used for the unilateral group (8xthreshold) for one trial (9) and/or use of thriceweekly ECT (9, 13) as both result in larger cognitive deficits.
Strengths and weaknesses
Trial strengths include non-inferiority design, pragmatic attitude, relatively large sample size and adequate power. We showed excellent adherence and end-of-treatment completion rates.
Retention at both follow-ups was satisfactory for the primary and main cognitive outcomes and superior to previous relevant trials. Indeed, existing efficacy trials either lacked follow-up (8, 12, 13) , had shorter follow-ups (1-2 months) (9, 10) and/or had smaller follow-up samples (19-22 per group) (9, 11). None was designed to test non-inferiority of high-dose unilateral ECT compared to bitemporal ECT. The randomised sample was representative of the general population referred for ECT and similar to potentially eligible non-participants. Our findings, therefore, have good generalisability to countries where twice-weekly ECT is normal practice.
Our study has some limitations. First, we did not include involuntary patients who could not consent due to illness severity (7.4% of referrals) for whom bitemporal ECT may be better(13). Second, other than for autobiographical memory, there are high levels (13-54%) of missing variables for secondary cognitive outcomes at follow-ups. Nevertheless, this study presents the best available evidence of long-term cognitive correlates of high-dose unilateral and bitemporal ECT. A third limitation concerns the Autobiographical Memory Interview. We selected this instrument to situate our trial within existing research evidence as most previous trials used a variant of it (8, (11) (12) (13) . However, it does not allow quantification of retrograde amnesia attributable directly to ECT even though it is sensitive in detecting differences between treatment allocations on autobiographical memory recall (6, 7, 34, 35) . Nevertheless, the present trial shows that high-dose unilateral ECT affects autobiographical memory less than Fifth, the relatively lower remission rate may be due to the pragmatic design when compared to other trials (8-13) performed under more stringent, but less clinically general, conditions.
CONCLUSIONS
Our study has important clinical implications. In terms of harms/benefits ratio, high-dose unilateral ECT is non-inferior to bitemporal ECT but showed a better cognitive profile, especially for preserving retrograde personal memories and fewer subjective cognitive sideeffects. While there is much interest in other modifications to maintain effectiveness but reduce side-effects, e.g. ultrabrief pulse-width ECT, these require further refinement and characterization for optimisation (36, 37). Our findings justify considering high-dose unilateral ECT as the preferred ECT option for treating depression and may help improve acceptability and availability of this effective treatment. (3) . The presence of any of these factors was incorporated into the dose titration algorithm to tailor the process to the individual patient by beginning at one level higher for each one of these factors when present. For example, in the titration procedure shown in Table S1 , the initial stimulus dose for a young adult female undergoing unilateral ECT would be at the lowest level, i.e. 25 mC. However, if she was over 65 years old and taking regular benzodiazepines, the initial stimulus dose would be increased by two levels up to 75 mC.
Patients were stimulated at the appropriate initial level. If an adequate seizure was not produced, then the patient was restimulated one level higher (see Table S1 ). There was an interval of at least 30 seconds before each restimulation. If an adequate seizure was still not produced after the second attempt, and anaesthetic conditions permitted, the patient was restimulated for the second time at another two levels higher, i.e. one level was skipped. If in the first session a third stimulation was required and resulted in an adequate seizure, the seizure threshold could have been either the dose used or the previous (i.e. skipped) level.
Therefore, the second session began with the skipped dose level to clarify the seizure threshold.
Once the seizure threshold was established, subsequent treatments were given at 1.5xthreshold for bitemporal and 6xthreshold for unilateral (d'Elia placement) ECT. Seizure threshold can substantially rise over the course of ECT and this may be manifested in a progressive shortening in seizure duration. The aim of the treatment is to ensure that the dose clearly remains suprathreshold (2) . Therefore, if the EEG seizure duration fell by >20%
relative to the second session then the initial stimulus dose was raised in the next session by Table S1 ). This new level was adopted as the initial dose for subsequent sessions.
HANDLING OF MISSING DATA
In the presence of missing data, the resulting (maximum likelihood) 
